List Of Priority Medical Devices For
Management Of Cardiovascular Diseases And Diabetes
The WHO List of Priority Medical Devices for
management of cardiovascular diseases and diabetes, released recently , will
help policy-makers and health-care providers prioritize the selection and
procurement of medical devices for these health conditions. It includes more
than 500 devices that are required at all levels of the health system, from
primary care facilities to highly specialized hospitals, and devices needed for
health emergencies such as cardiac arrest, stroke and hypo or hyper glycaemic
The new List provides clinical guidelines for
specific conditions, describes the relevant interventions required (e.g.
hospitalization, cardiac surgery, intensive care, laboratory testing and medical
imaging) and subsequently lists all the medical equipment required such as
surgical instrument sets, personal protective equipment, and diagnostic and
The ultimate aim of this new List is to help
health-care providers implement interventions that are essential for the
detection and management of heart conditions and diabetes across the continuum
of care, leading to fewer hospitalizations and deaths and the saving of precious
Non-communicable diseases (NCDs) – which include
cardiovascular diseases and diabetes – represent 74% of global annual deaths and
are responsible for more than 15 million people dying prematurely each year
between the ages of 30 and 69. Low- and middle-income countries bear 85% of the
burden of these premature deaths, largely because they lack the testing and
monitoring equipment needed to screen for, diagnose and treat NCDs.
Along with the List, WHO has developed MeDevIS, a
medical devices information system and clearing house where biomedical
engineers, public policy-makers and hospital managers can find more information
on specific medical devices, their use and how to look after them. The site
currently lists 1500 devices and will continue to be updated for other diseases
and health conditions.
The list is part of a series of lists prioritizing
devices for highburden diseases, including cancer and COVID-19. These lists are
based on the best available evidence about the essential medical devices
countries need to prevent, diagnose and treat disease. They should be adapted to
national contexts and used to update or develop national lists. Ultimately, the
lists are meant to help countries increase the availability and appropriate use
of medical devices and to promote access to better quality health services.
The full set of lists are the global reference for
countries to develop or update their national lists for public procurement and
reimbursement of devices for screening, diagnosis and treatment of disease. They
also help them to ensure value for money and ultimately to increase access.
Abstracts from Concluding Remarks of the Report.
The present publication was completed thanks to a
collaboration between interdisciplinary experts from around the world, as well
as supportive nongovernmental organizations. It is envisioned that these lists
of medical devices classified by clinical unit will assist policy-makers, health
care managers and technical experts to define the needs of each setting and to
inform the development or update of the national medical devices lists approved
for procurement or reimbursement, towards universal health coverage.
Medical devices run the substantial risk of being
unused due to technology misalignment with deployment settings . Contextually
relevant interventions and devices must be selected to improve resource
allocation in each country, depending on the local needs and resources
available. Financing models are also an important consideration, and their
ability to deliver services within health care systems should be carefully
evaluated. The lists presented in this publication should be adapted by a local
committee to different cultural norms and reviewed according to local
epidemiology, national policies, regulatory frameworks, and the available
specialized health care workforce, infrastructure, budget, and organizational
structures. It is therefore important to consider innovation, regulatory
approval of the technologies, and the health technology assessment process to
enable informed decision-making, taking into consideration equity, social,
clinical and economic aspects as well as health technology management aspects.
Such informed decision making will ensure that the procurement, installation,
training and safe use of technologies is done in the most effective way,
ensuring the well-being of the patient.
The selection of the technologies required from the
lists presented in this publication is just the first step of many to provide
best care for patients. These technologies require multidisciplinary expertise
to be implemented. More information will be available from WHO and other
agencies to support selection, procurement and best use of these medical devices
for all patients and specifically to target management of NCDs.
Much work is still needed in order to increase
access to the appropriate, good-quality medical technology required to prevent,
diagnose, treat, and monitor NCDs worldwide, including cardiovascular diseases
and diabetes, and to develop the human resource competencies of specialized
interventions and ensure financial resources to provide the services under the
universal health coverage initiative.
The recent COVID-19 global situation calls for
prioritizing investment in prevention and management of health. It has been
noted that population with NCDs are more prone to have COVID-19 complications,
therefore the prevention and management of NCDs is of paramount importance and
thus, important to have access to the medical devices required for them.